ACE-031: Phase I data

Data from a dose-escalation, Canadian Phase I trial in 48 healthy volunteers showed that single subcutaneous doses of 1 mg/kg and 3 mg/kg ACE-031 increased lean body mass at day 57 by 2.4% and 2.6%, r...